• NICE Gives Thumbs-Up to Heart Device

    In guidance released on 18 December 2013, the UK's National Institute for Health and Care Excellence (NICE) recommended Jotec's E‑vita open plus device for treating complex aneurysms and dissections of the thoracic aorta, in a carefully selected group of people. The E-vita open plus is a modified graft prosthesis, specifically designed for one-stage repair in complex aortic disease through median sternotomy. It consists of two sections joined together which allows two a...
  • NICE Recommends Genzyme’s Aubagio for MS

    The UK's National Institute for Health and Care Excellence (NICE) on 6 December 2013 issued a final appraisal determination (FAD) recommending reimbursement for Genzyme's multiple sclerosis drug Aubagio (teriflunomide).  The recommendation is for treatment of adults with active relapsing-remitting multiple sclerosis (RRMS), normally defined as two clinically significant relapses in the previous two years. NICE is limiting its recommendation to patients who do no...
  • New Wound Treatment Device Gets Preliminary Recommendation from NICE

    The UK's cost containment agency, the National Institute for Health and Care Excellence (NICE), issued draft guidance  on 14 November 2013 recommending the use of the Debrisoft monofilament debridement pad for treating chronic wounds, such as pressure and leg ulcers, and acute wounds such as those occurring from a burn or as a complication of surgery.   The device is a single-use polyester pad that improves wound healing, and would save the National Health Ser...
  • NICE Asks Janssen for More Data for Multiple Myeloma Drug

    The UK's cost containment agency, the National Institute for Health and Care Excellence (NICE), has issued draft guidance asking Janssen to provide more data on the effectiveness of bortezomib (Velcade) for treating patients with newly diagnosed multiple myeloma. NICE is evaluating the use of bortezomib in combination with dexamethasone and thalidomide, and has also requested further evidence on the clinical and cost effectiveness of the bortezomib/dexamethasone combi...
  • NICE Opens Consultation on Geko Device to Reduce Risk of VTE

    The National Institute for Health and Care Excellence (NICE) has opened a consultation on draft medical technology guidance on a device designed to reduce the risk of venous thromboembolism (VTE) in a deep vein of the legs. The draft guidance acknowledges that the geko device shows potential to reduce the risk of VTE, but says that there is currently insufficient evidence of its clinical effectiveness to support a recommendation for routine adoption in the NHS.  NI...
  • Novartis’ CNV Drug Lucentis Gets OK from NICE

    The UK's cost containment agency, the National Institute for Health and Care Excellence (NICE), issued  final draft guidance  on 25 October 2013 recommending reimbursement for Novartis' Lucentis as a treatment option for choroidal neovascularisation (CNV). CNV is characterized by the growth of new blood vessels at the back of the eye in people with a rare form of short-sightedness known as pathological myopia.  NICE's recommendation is qualified by the c...
  • NICE Clears MSD and Roche Hepatitis C Drugs for Reimbursement

    The UK's cost containment agency, the National Institute for Health and Care Excellence (NICE), issued final draft guidance  on 10 October 2013 confirming its earlier draft guidance recommending peginterferon alfa in combination with ribavirin as an option for treating chronic hepatitis C in children and young people.  Ribavirin is manufactured by Roche Products (Copegus) and MSD (Rebetol). NICE's Appraisal Committee concluded that treatment with peginterfer...
  • UK’s NICE Gives Green Light to IVDs for Colorectal Cancer Treatment

    The UK's cost containment agency, the National Institute for Health and Care Excellence (NICE), issued draft guidance on 3 October 2013 recommending reimbursement for four in vitro diagnostic tests (IVDs) used for determining the KRAS mutation status in adults with metastatic colorectal cancer. The tests are used by doctors to help them target more effective treatments for those patients with metastatic colorectal cancer. The four recommended tests are: Therascreen ...
  • NICE Recommends Test for Bowel Disease

    The UK's cost containment agency, the National Institute for Health and Care Excellence (NICE), has issued guidance advising doctors to use the faecal calprotectin test as an option to distinguish between potentially serious inflammatory bowel disease (IBD) and less serious irritable bowel syndrome (IBS). According to NICE, the test will reduce both the time spent searching for a diagnosis and the invasive procedures currently used such as colonoscopy. It is also like...
  • Roche’s MabThera Wins NICE Recommendation for Autoimmune Condition

    The UK's cost containment agency, the National Institute for Health and Care Excellence (NICE), has issued draft guidance recommending reimbursement for Roche's MabThera (rituximab) as an option for treating some adults with the rare autoimmune condition, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (severely active granulomatosis with polyangiitis [GPA] and microscopic polyangiitis). MabThera is a genetically engineered chimeric (mouse/human) mon...
  • Genomic’s Breast Cancer IVD Gets Green Light from UK’s NICE

    The UK cost containment agency, the National Institute for Health and Care Excellence (NICE), r ecommended on 25 September 2013 that the Oncotype DX test (Genomic Health) should be reimbursed by the National Health Service (NHS) as an option to help clinicians decide whether to prescribe chemotherapy to patients with early breast cancer. The test measures the presence of biological characteristics within a tumor that may indicate how it is likely to grow and whether it...
  • NICE Asks Genzyme for More Cost Effectiveness Data for its MS Drug

    The UK's cost containment agency, the National Institute for Health and Care Excellence (NICE), issued draft guidance on 18 September 2013 that requests more data from Genzyme on teriflunomide (Aubagio) as a treatment for adults with relapsing-remitting multiple sclerosis.  The draft noted that the drug is being considered as a first-line treatment option alongside glatiramer acetate and the beta interferons, and administration of the drug would be stopped if the...